NICE says yes to Novartis’ multiple sclerosis therapy Kesimpta
pharmaphorum
APRIL 20, 2021
NICE’s final appraisal document for Kesimpta will be followed by technology appraisal guidance (TAG) that will pave the way for NHS prescribing in England and Wales. While it requires a clinic visit, Ocrevus only has to be administered twice a year. GlobalData thinks Ocrevus will remain the most widely-used option, hitting $7.6
110 
Let's personalize your content